<DOC>
	<DOCNO>NCT00002462</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy combination chemotherapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy radiation therapy follow chemotherapy treat patient stage III stage IV Hodgkin 's disease .</brief_summary>
	<brief_title>RT No RT Following Chemotherapy Treating Patients With Stage III/IV Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Compare relapse-free survival overall survival patient Stage III/IV Hodgkin 's disease randomly assign adjuvant involved-field radiotherapy vs. adjuvant therapy follow remission induction MOPP/ABV ( nitrogen mustard/vincristine/procarbazine/prednisone/doxorubicin/bleomycin/vinblastine ) . II . Evaluate therapeutic efficacy MOPP/ABV hybrid chemotherapy advance Hodgkin 's disease . III . Evaluate prognostic significance early response MOPP/ABV patient advance Hodgkin 's disease . OUTLINE : Study randomize adjuvant radiotherapy . All patient receive Induction chemotherapy Regimen A , follow CR randomize Arms I II . Regimen A : 7-Drug Combination Chemotherapy . MOPP/ABV Hybrid . Mechlorethamine , NM , NSC-762 ; Vincristine , VCR , NSC-67574 ; Procarbazine , PCB , NSC-77213 ; Prednisone , PRED , NSC-10023 ; Doxorubicin , DOX , NSC-123127 ; Bleomycin , BLEO , NSC-125066 ; Vinblastine , VBL , NSC-49842 . Arm I : Radiotherapy . Involved-field irradiation use megavoltage equipment . Arm II : No therapy . PROJECTED ACCRUAL : 321 evaluable patient require ; annual accrual rate 80 patient anticipate .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven clinical pathological Stage III/IV Hodgkin 's disease Pathological Stage IIIAS disease spleen site subdiaphragmatic involvement exclude PATIENT CHARACTERISTICS : Age : 15 70 Performance status : Not specify Life expectancy : No severe limit life expectancy due nonmalignant disease Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No severe cardiac disease would preclude protocol therapy Pulmonary : No severe pulmonary disease would preclude protocol therapy Other : No severe metabolic neurologic disease would preclude protocol therapy No concomitant previous second malignancy except : Nonmelanomatous skin cancer In situ carcinoma cervix PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
</DOC>